日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

KATHERINE 研究显示,对于 HER2 阳性乳腺癌且存在 HER2 阴性残留浸润性疾病的患者,辅助曲妥珠单抗-美坦新治疗效果良好。

Loibl, Sibylle; Huang, Chiun-Sheng; Mano, Max S; Mamounas, Eleftherios P; Geyer, Charles E Jr; Untch, Michael; Thery, Jean-Christophe; Schwaner, Ingo; Limentani, Steven; Loman, Niklas; Lübbe, Kristina; Chang, Jenny C; Hatschek, Thomas; Tesarowski, David; Song, Chunyan; Lysbet de Haas, Sanne; Boulet, Thomas; Lambertini, Chiara; Wolmark, Norman

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial

利用核心针穿刺活检的21基因检测选择乳腺癌新辅助治疗方案:一项多中心试验

Bear, Harry D; Wan, Wen; Robidoux, André; Rubin, Peter; Limentani, Steven; White, Richard L Jr; Granfortuna, James; Hopkins, Judith O; Oldham, Dwight; Rodriguez, Angel; Sing, Amy P